R. Langley, “Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials”, J of Skin, vol. 6, no. 2, p. s1, Mar. 2022.